Collaborators
University of Liverpool, University of Southampton, University of Nottingham, Imperial College London. MOSAIC, Responing to the pandemic (H1N1) 2009 outbreak, 2009 - 2012
Tim Sparwasser, Institute for Infection ImmunologyCentre of Experimental and ClinicalTwincoreFeodor-Lynen-Straße 7Hannover30625Germany, 2008
Dr Peter Collins, National Institute of HealthBethesdaMaryland 20892USA, 2003
Dr Anne O'Garra, National Institute for Medical Research, 1985
Alexander Bukreyev, Laboratory of Infectious DiseasesNational Institute of Allergy and InNational Institutes of Health50 South Dr., Rm. 6505,Bethesda, MD20892-8007USA
Guest Lectures
Is flu a disease of immune failure of excess?, ESWI, PREPARE Symposium, Riga Latvia, 2017
Matching RSV vaccines and treatments to target groups, European Respiratory Society, London, 2017
Who gets severe influenza and why?, European Respiratory Society, London, 2017
Protective and harmful immune responses to respiratory viral infections, BSI Summer School, Leicester, 2017
The role of bacteria in severe influenza, 5th ISIRV-AGV Conference, Shanghai, 2017
Antiviral drugs for RSV disease what is the potential?, 5th ISIRV-AGV Conference, Shanghai, 2017
Viral lung disease pathogenesis and prospects for vaccination, University of Edinburgh, Edinburgh, 2017
The challenge of studying human infections RSV and influenza, University of Birmingham, Birmingham, 2017
Life: an experiment, Society for Research and Academia, SORA London, 2017
What can we learn from human challenge studies with RSV?, ReSViNET, Amsterdam, 2017
Summary of the current and future dialogue in the field of RSV, Global RSV Symposium, Bariloche, Argentina, 2016
Protective and harmful responses to respiratory challenge, Addenbrooke's Hospital, Cambridge, 2016
Exacerbation of airway disease, Options IX ISIRV, Chicago, 2016
Defence against viruses at the respiratory mucosa, Society for Mucosal Immunology, Berlin, 2015
Special features of the uniquely vulnerable lung, Society for Mucosal Immunology, Berlin, 2015
Immune response to influenza and antiviral treatment, EAACI, Barcelona, 2015
Respiratory syncytial virus and the lung, ATS, Denver, 2015
Protective Immunity, BBSRC 1st Vaccinology Network Conference, Birmingham, 2015
Personalised routes to protection and disease in respiratory viral infections, Centre for Translational Science, Pasteur Institute, Paris, 2015
The predictive value of immunological responses in the murine model for human disease, RSV Workshop, Oxford, 2015
‘Meet the Experts: Bronchiolitis’, Excellence in Paediatrics, Florence, Italy, 2010
‘Swine flu and pregnancy’, Maternal and Women’s Health conference, 2010
Session Chair, World Immune Regulation meeting III, Davos, Switzerland, 2009
‘Regulation of host responses to lung infections’, Yorkshire Immunology Group, 2009
‘Vaccination and Immunotherapy of Viral Diseases’, ECI workshop Chair, 2009
‘Pandemic: Does the Global Media spread information or panic?, BBC Global News debate panel, 2009
‘The science of pandemics’, The D Group, Speaker and Guest of Honour, 2009
‘Microbes and host-defence in lung disease’, British Thoracic Society, 2009
‘The 2009 Swine Flu Pandemic-UK Strategy and Lessons Learnt’, Royal College of Physicians, Advanced Medicine, 2009
’Clinical manifestations of influenza and complications’, European Respiratory Society, 2009
Pro-con debate on viruses and asthma, AAAAI-USA, USA, 2008
‘Effect of age, experience and maturity on viral lung disease’, Keynote speaker, Croatian Immunological Society, Croatia, 2008
‘Regulatory cells and Th17 cells’, World Immune Regulation Meeting II, Davos, Switzerland, 2008
‘Respiratory Syncytial virus and the pathogenesis of asthma’, University of Edinburgh Symposium, Edinburgh, Scotland, 2008
‘Newly identified associations between viral bronchiolitis and asthma’, 2nd National Conference Paediatric Asthma and Allergy, 2008
Guest speaker, The 3rd European Influenza Conference, Portugal, 2008
Plenary speaker, European Society for Clinical Virology, Lyon, France, 2007
Speaker, European Respiratory Society, Stockholm, 2007
Speaker, Beijing Forum on Emerging Diseases, Beijing, 2007
‘Targeting common viruses with antivirals and vaccines: is there hope?’, AAAAI, San Diego, USA, 2007
RSV vaccines: past, present and future, Health Protection Agency, Colindale, London, UK, 2006
Avian Influenza: Origins, transmission and disease, Avian flu: summit for Buisness, Olympia, London, UK, 2006
Avian influenza, National Heart and Lung Institute, London, 2006
Mechanisms of RSV-related BHR and lung disease, Frankfurt, Germany, 2006
‘Scientific Issues in Vaccination’, Health Protection agency, 2006
Session Chair, 16th European Congress of Immunology, Paris, France, 2006
‘Immune effects of common cold viruses and allergy: what do they share?', Paediatric Allergy Workshop, 2006
‘Vaccines’, Immunology course for clinicians and scientists, 2006
‘Host immunity to respiratory viruses: Protective and disease causing effects’, 2nd FEMS Congress of European Microbiologists, 2006
Avian Influenza: the current threat, Annual Student Prize Award ceremony, Imperial College, 2005
Viruses in asthma and COPD, ERS Congress, Copenhagen, 2005
Common colds and asthma: good, bad or indifferent?, British Association for the Advancement of Science, Dublin, Ireland, 2005
Mechanisms of inflammation in RSV disease, Oxford University, Wetherall Institute (for Molecular Medicine), 2005
Anti-viral immunity and disease, Transatlantic Airways Conference, Key Biscane, FL, USA, 2005
The role of experts in guiding policy: the immunologist's perspective, ESWI, PREPARE Symposium Riga, Latvia
Research Student Supervision
Affendi,S, Role of Macrophages in defence against respiratory infection
Affendi,SS, ‘Invariant Natural Killer T (iNKT) cell activation and Th2 immunity in the lung’
Cherrie,A, ‘Human immune responses to respiratory syncytial virus’
Dodd,J
Dunning,J, ‘Disease mechanisms in severe human influenza’
Farhadi,N, ‘The role of innate lymphocytes in the development of allergic airway inflammation’
Guvenel,A, Follicular helper T cells and antibody responses to human RSV infection
Habibi,M, ‘Immunoregulation in the respiratory tract after human volunteer infection with RSV’
Harker,J, ‘Effect of Recombinant Cytokine Expression on Priming, Pathology and Protection Against Viral Infection of the Lung’
Helsen,R, Helson ‘DNA Vaccination against Respiratory Syncytial Virus (RSV) using PLG Microparticle Adjuvant’
Jha,A, The effects of atopy and asthma on in vivo human nasal responses to Toll-like receptor agonists
Lee,D, ‘Regulation of immune responses and viral persistence in RSV infection’
Lobbermann,J, ‘Role of Regulatory T cells in the control of viral exacerbations of asthma’
Maher,C, Use of reverse genetics to study the role of respiratory syncytial virus attachment protein G in lung immunopathology’
Matthews,S, Immune Mechanisms of Respiratory Syncytial Virus Disease’
O'Donnell,R, The delayed effect of RSV Ifection
Patel,A, Relationship between airway infection, exacerbations and severity of cardiovascular risk in COPD’
Pennycook,A, The role of chemokines in lung disease induced by respiratory syncytial virus infection’
Peters,N, ‘Lentivirally Transduced Dendritic Cells Over-Expressing IL-4, IL-10 and IL-12 - Effects on RSv and Allergen Induced Airway Inflammation and Changes in Lung Function
Pribul,P, ‘The role of innate cells and their mediators in RSV’
Sande,C
Spender,L, Cytokine expression in immunopathology induced by RSV
Wythe,S, ‘The role of pulmonary dendritic cells in polarised CD4 T cell-recall responses to infection with respiratory syncytial virus’
Yamaguchi,Y, ‘Environmental effects on maturation of lung structure and immune defences’